DOCSLIB.ORG

Nitrates, Nitrites, and N-Nitroso Compounds

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nitrates, Nitrites, and N-Nitroso Compounds This report contains the collective views of an international group of experts and does not necessarily represent the deci- sions or the stated policy of either the World I-Iea]th Organization or the United Nations Environment Programme Environmental Health Criteria 5 NITRATES, NITRITES, AND N-NITROSO COMPOUNDS Published under the joint sponsorship of ... the United Nations Environment Programme and the World Health Organization (6 Y. y I / t:3 / A World Health Organization Geneva, 1978 I 7 ISBN No. 92 4 154065 6 © World Health Organization 19711 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or in tow, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers' products does not imply *-- that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are dislinguished by initial capital letters. PR1NTD IN UNITED KINGDOM CONTENTS Pg ENVIRONMENTAL HEALTH CRITERIA FOR NITRATES, NITRITES A N D N- N ITROSO COM POU N DS .................... II L. SUMMARY AND RECOMMENDATIONS FOR FURTHER STUDIES 13 1.1 Summary ............................ 13 1.1. 1 Analytical methods ................... 13 1 1.1.1 Nitrates and nitrites ................ 13 l 1.1.2 N-nitroso compounds ................. 13 1 1.2 Sources and occurrence in the environment ........... 14 1.1.2.1 Nitrates and nitrites ................. 14 1.12.2 N-nitroso compounds ................. 14 11.3 Metabolism ....................... 15 1.1.3.1 Nitratesand nitrites ................ 15 1.1.3.2 N-nitroso compounds ................. IS 1.14 Experimental studies in animals ................ IS 1.1.4.1 Nitrates and nitrites ................ 15 14.2 N-nitroso compounds ................ 16 1.1 5 Epidemiological studies .................. 16 1.1.5.1 Nitrates and nitrites ............... 16 1.1.5.2 N-nitrosocompounds ................. 17 .1.6 Evaluation of health risks .................. 17 .1.6. I Nitrates and nitrites ................. 17 1.1.62 N-nitrosoeompounds ................ 17 1.2 Recommendations for further studies ................ IS 12.1 Analyticalproblems .................... 18 12.1.1 Nitrates and nitrites ............. 18 121.2 N-nitrosocompounds ................ 18 12.2 Sources and levels in the environment ............. 18 12.2.1 Nitrates and nitrites ................ 18 12.2.2 N-nitroso compounds ................ 19 12.3 Metabolism ......................... 19 1.2.3.1 Nitrates and nitrites ............... 19 1.2.3.2 N-nitroso compounds ................. 20 1.2.4 Experimental studies .................... 20 12.5 Epidemiological and clinical studies ............. 20 1.2.5.1 Nitrates and nitrites ................. 20 1.2.5.2 N-nitroso compounds ................ 20 2. CHEMISTRY AND ANALYTICAL METHODS ............21 2.1 Chemical properties and reactions .................21 2.1.1 Nitrates and nitrites ..................2 I 11.2 N-nitrosocompounds ....................21 2.1.3 Formation of N-nitroso compounds in idro ........... 22 2.1 4 The effects of other substances on the formation of N-nitroso compounds ..................... 25 2.2 Analytical methods ......................26 2.2.1 Nitrates and nitrites .....................26 2.2.2 N-nitroso compounds ....................27 3 Page I SOURCES OF NITRATES, NiTRITES AND N-NITROSO COMPOUNDS IN AIR. WATER, SOIL, AND FOOD .................30 3.1 Natural occurrence .....................30 3.1.1 Nitrates and nitrites ...................30 3.1.2 2s-nitroso compounds .................30 3.2 Sources related to man's activities .................31 3.2.1 Nitrates and nitrites ....................II 3.2.1.1 Ecrtiliiers.....................11 3.2.1.2 Animal wastes ...................31 3.2.1.3 Municipal, industrial, and transport wastes ....... 32 3.2.1.4 Deliberate addition of nitrates and nitrites to food ..... 32 3.2.2 N-nitroso compounds .................. 33 3.2.2.1 Food .................... 33 3,2.2.2 Tobacco .................... 33 3.2.13 Industrial uses ..................... 4. TRANSPORT AND TRANSFORMATION IN ENVIRONMENTAL AND I4IOLOGICAL MEDIA .....................34 4,1 Nitrogen Cycle ........................ 4.2 Transformation in food ....................16 4.2.1 Reduction of nitratcs to nitrites .................16 4.2.2 Formation and degradation of N-nitroso compounds .......17 4.3 Formation of N-nitroso compounds from drugs and pesticides ....... 44 Formation ol \-flitroSo conipounds in animal organisms .........39 4.4.1 Formation of V-nitroso compounds in simulated gastric juice 39 4.4.2 Formation of ,•\-nitroso compounds in rig o ............19 4.5 Formation of A-nitroso compounds by microorganisms ........40 46 The effects of other chemicals on the formation of A-nitroso compounds - 40 5. FNVIRONMFNTAL LEVELS AND EXPOSURES ...........41 SI Nitrates and nitrites ................... 41 5 1.1 Ambieril air .................... 41 5.1.2 Water ......................... 41 5.I.3 Selected foods .................... 43 5.1.4 Estimate of general population exposure ............ 44 5.2 -\n1troso compounds .................... 45 5.2.1 Ambient air ..................... 45 5.22 Water ..................... 45 5.2.3 Selected foods ...................... 45 524 Tobacco and tobacco smoke ................. 49 5 Estimate of general population exposure .......... 49 5.2.6 Occupational exposure to A-'-nitroso compounds ....... 50 6. ME'I'ABOLISM OF NITRATES, NITRITES, AND ,.V-NITROSC) COMPOUNDS ..........................50 6 1 Gastrointestinal absorption ..................50 6.1.1 Nitrates and nitrites ...................50 6.1.2 2sunitroso compounds ...................SI 6.2 Biotransformation and eliminalion .................SI 6.2 I Nitrates and nitrites .................SI 6.2.2 V-nitroso compounds ................51 4 Pgc 7. EXPERIMENTAL ANIMAL STUDIES ON THE EFFECTS OF NITRATES, NITRITES.AND,V-NITROSOCOMPOUNDS .............. 52 7.1 Nitr tea and nitrites ....................... 52 7.1.1 Acute and subacute toxicity studies .............. 52 7.1.2 Chronic toxicity and carcinogcnicity studies .......... 54 7.1.3 Emhryotoxicity ..................... 55 7.1.4 Mutagenicity ........................56 7.1.5 Interaction with nutritional factors ............... 57 7.2 A-nitroso compounds ....................... 57 7.2, I Acute and subacute toxicity studies .............. 57 7.2.2 Careinogenicity ...................... 59 7.2.2.1 Interspecies variation in response ........... 61 7.2.2.2 Intraspecies variation in response ........... 61 7.2.2.3 Dose-response relationships of N-nitroso compounds 62 7.2.2.4 Tumour induction by combined administration of nitrites, and amines or am ides ................. 63 7.2.2.5 Dose-response relationship for combinations of nitrites and amines ...................... 65 7,2.2.6 Transplacental carcirlogenesis ............ 66 7.2.2.7 Morphological studies ............... 67 72.18 Biochemical mechanisms ............... 68 7.2.2.9 Interaction with various chemical factors ........ 68 7.2.2.1 t) Miscellaneous modilying factors ............ 70 7.2.3 Embryotoxicity and teratogenicity ..............71 7.2.4 Mutagenicity ......................71 8. EFFECTS OF NITRATES, NITRITES, AND N-NITROSO COMPOU NDS ON MAN .............................73 81 Nitrates and nitrites .......................73 8.1.1 Epidemiological studies..................73 8.1.1.1 Exposure through water ................74 8.1.1.2 F,xposure through vegetables ..............76 811.3 High accidental exposures ...............76 8.1.1.4 Ambient air exposures ...............76 8.1.2 Factors involved in susceptibility to nitrates ...........77 8.1.3 Dose-response relationships for nitrates and nitrites ........78 8.2 N-nitroso compounds ......................80 9. EVALUATION OF HEALTH RISKS TO MAN FROM EXPOSURE TO NITRATES. NITRITES. AND N-NITROSO COMPOUNDS ........ 81 9.1 Nitrates and nitrites ........................ 81 9.1.1 General considerations ................... 81 9.1.2 Assessment of health risks ................. 82 9.2 N-nitroso compounds ....................... 9.2.1 General considerations ................... 83 9.12 Assessment of health risks .................. 83 9.3 Reduction ofexposureth ....................... 84 REFERENCES ........................... 85 S NOTE TO READERS OF THE CRITERIA DOCUMENTS While every effort has been made to present information in the criteria documents as accurately as possible without unduly delaying their publication, mistakes might have occurred and are likely to occur in the future. In the interest of all users of the environmental health - criteria documents, readers are kindly requested to communicate any errors found to the Division of Environmental Health, World Health Organization, Geneva, Switzerland, in order that they may he included in corrigenda which will appear in subsequent
Load more

Recommended publications
  • Nitroso and Nitro Compounds 11/22/2014 Part 1
    Hai Dao Baran Group Meeting Nitroso and Nitro Compounds 11/22/2014 Part 1. Introduction Nitro Compounds O D(Kcal/mol) d (Å) NO NO+ Ph NO Ph N cellular signaling 2 N O N O OH CH3−NO 40 1.48 molecule in mammals a nitro compound a nitronic acid nitric oxide b.p = 100 oC (8 mm) o CH3−NO2 57 1.47 nitrosonium m.p = 84 C ion (pKa = 2−6) CH3−NH2 79 1.47 IR: υ(N=O): 1621-1539 cm-1 CH3−I 56 Nitro group is an EWG (both −I and −M) Reaction Modes Nitro group is a "sink" of electron Nitroso vs. olefin: e Diels-Alder reaction: as dienophiles Nu O NO − NO Ene reaction 3 2 2 NO + N R h 2 O e Cope rearrangement υ O O Nu R2 N N N R1 N Nitroso vs. carbonyl R1 O O O O O N O O hυ Nucleophilic addition [O] N R2 R O O R3 Other reaction modes nitrite Radical addition high temp low temp nitrolium EWG [H] ion brown color less ion Redox reaction Photochemical reaction Nitroso Compounds (C-Nitroso Compounds) R2 R1 O R3 R1 Synthesis of C-Nitroso Compounds 2 O R1 R 2 N R3 3 R 3 N R N R N 3 + R2 2 R N O With NO sources: NaNO2/HCl, NOBF4, NOCl, NOSbF6, RONO... 1 R O R R1 O Substitution trans-dimer monomer: blue color cis-dimer colorless colorless R R NOBF OH 4 - R = OH, OMe, Me, NR2, NHR N R2 R3 = H or NaNO /HCl - para-selectivity ΔG = 10 Kcal mol-1 Me 2 Me R1 NO oxime R rate determining step Blue color: n π∗ absorption band 630-790 nm IR: υ(N=O): 1621-1539 cm-1, dimer υ(N−O): 1300 (cis), 1200 (trans) cm-1 + 1 Me H NMR (α-C-H) δ = 4 ppm: nitroso is an EWG ON H 3 Kochi et al.
    [Show full text]
  • Meat Curing and Sodium Nitrite
    MEDIA MYTHCRUSHER Meat Curing and Sodium Nitrite The use of nitrite to produce cured meats like salami, ham, bacon and hot dogs, is a safe, regulated practice that has distinct public health benefits. However, much confusion and even mythology surrounds nitrite. Being mindful of key words and statistics and providing appropriate context can help reporters improve the accuracy of their coverage and the information that is passed on to readers and viewers. We’ve compiled ten tips to improve accuracy when writing about the use of sodium nitrite in cured meats. #1: Nitrite is not ‘unnatural’. Before the terms nitrate and nitrite are often used refrigeration was available, humans salted and interchangeably, meat companies mainly use dried meat to preserve it. It was discovered sodium nitrite to cure meat, not sodium nitrate. that the nitrate in saltpeter was extremely At the turn of the 20th century, German effective in causing a chemical reaction known scientists discovered nitrite (and not nitrate) as “curing.” Not only did this give meat a was the active form of these curing salts. When distinct taste and flavor, it also preserved it and added directly, rather than as nitrate, meat prevented the growth of Clostridium botulinum, processors can have better control of this which causes botulism. important curing ingredient and more closely manage how much they are adding. Later on, scientists came to understand that nitrate naturally found in the environment #3: Cured meats are a miniscule source of converts to nitrite when in the presence of total human nitrite intake. Scientists say that certain bacteria.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Inhibition of Grb2‑Mediated Activation of MAPK Signal Transduction
    566 ONCOLOGY LETTERS 4: 566-570, 2012 Inhibition of Grb2‑mediated activation of MAPK signal transduction suppresses NOR1/CB1954‑induced cytotoxicity in the HepG2 cell line RONG GUI1, DENGQING LI1, GUANNAN QI1,2, ALI SUHAD2 and XINMIN NIE1 1Clinical Laboratory Centre of the Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China; 2Hormones and Cancer Research Unit, Royal Victoria Hospital, McGill University, Quebec H3A 1A1, Canada Received March 12, 2012; Accepted June 22, 2012 DOI: 10.3892/ol.2012.774 Abstract. The nitroreductase oxidored-nitro domain Introduction containing protein 1 (NOR1) gene may be involved in the chemical carcinogenesis of hepatic cancer and nasopharyn- The oxidored-nitro domain containing protein 1 (NOR1) gene geal carcinoma (NPC). We have previously demonstrated that was previously cloned in our laboratory at the Third Xiangya NOR1 overexpression is capable of converting the monofunc- Hospital (Hunan, China) using suppression subtractive hybrid- tional alkylating agent 5-(aziridin-1-yl)-2,4-dinitrobenzamide ization and cDNA microarrays (1,2). By examining the human (CB1954) into a toxic form by reducing the 4-nitro group of genome working sequence, it has been identified that that the CB1954. Toxic CB1954 is able to enhance cell killing in the NOR1 gene is located on 1p34.3 and contains 10 exons and NPC cell line CNE1; however, the underlying mechanisms 9 introns. Additionally, the PROSITE database identified remain unknown. Using cDNA microarrays and quantitative two possible cAMP and cGMP-dependent protein kinase real-time PCR, we previously discovered that NOR1 increases phosphorylation sites, two tyrosine phosphorylation sites the expression of growth factor receptor-bound protein 2 and four N-myristoylation sites in NOR1.
    [Show full text]
  • Role of Sodium/Calcium Exchangers in Tumors
    biomolecules Review Role of Sodium/Calcium Exchangers in Tumors Barbora Chovancova 1, Veronika Liskova 1, Petr Babula 2 and Olga Krizanova 1,2,* 1 Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Dubravska cesta 9, 845 45 Bratislava, Slovakia; [email protected] (B.C.); [email protected] (V.L.) 2 Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic; [email protected] * Correspondence: [email protected]; Tel.: +4212-3229-5312 Received: 6 August 2020; Accepted: 29 August 2020; Published: 31 August 2020 Abstract: The sodium/calcium exchanger (NCX) is a unique calcium transport system, generally transporting calcium ions out of the cell in exchange for sodium ions. Nevertheless, under special conditions this transporter can also work in a reverse mode, in which direction of the ion transport is inverted—calcium ions are transported inside the cell and sodium ions are transported out of the cell. To date, three isoforms of the NCX have been identified and characterized in humans. Majority of information about the NCX function comes from isoform 1 (NCX1). Although knowledge about NCX function has evolved rapidly in recent years, little is known about these transport systems in cancer cells. This review aims to summarize current knowledge about NCX functions in individual types of cancer cells. Keywords: sodium-calcium exchanger; cancer cells; calcium; apoptosis 1. Background Intracellular calcium ions are considered the most abundant secondary messengers in human cells, since they have a substantial diversity of roles in fundamental cellular physiology. Accumulating evidence has demonstrated that intracellular calcium homeostasis is altered in cancer cells and that this alteration is involved in tumor initiation, angiogenesis, progression and metastasis.
    [Show full text]
  • ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity
    ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity Agency for Toxic Substances and Disease Registry Case Studies in Environmental Medicine (CSEM) Nitrate/Nitrite Toxicity Course: WB2342 CE Original Date: December 5, 2013 CE Expiration Date: December 5, 2015 Key • Nitrate toxicity is a preventable cause of Concepts methemoglobinemia. • Infants younger than 4 months of age are at particular risk of nitrate toxicity from contaminated well water. • The widespread use of nitrate fertilizers increases the risk of well-water contamination in rural areas. About This This educational case study document is one in a series of and Other self-instructional modules designed to increase the primary Case Studies care provider’s knowledge of hazardous substances in the in environment and to promote the adoption of medical Environmen- practices that aid in the evaluation and care of potentially tal Medicine exposed patients. The complete series of Case Studies in Environmental Medicine is located on the ATSDR Web site at URL: http://www.atsdr.cdc.gov/csem/csem.html In addition, the downloadable PDF version of this educational series and other environmental medicine materials provides content in an electronic, printable format. Acknowledgements We gratefully acknowledge the work of the medical writers, editors, and reviewers in producing this educational resource. Contributors to this version of the Case Study in Environmental Medicine are listed below. Please Note: Each content expert for this case study has indicated that there is no conflict of interest that would bias the case study content. CDC/ATSDR Author(s): Kim Gehle MD, MPH CDC/ATSDR Planners: Charlton Coles, Ph.D.; Kimberly Gehle, MD; Sharon L.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Exisulind, a Novel Proapoptotic Drug, Inhibits Rat Urinary Bladder Tumorigenesis1
    [CANCER RESEARCH 61, 3961–3968, May 15, 2001] Exisulind, a Novel Proapoptotic Drug, Inhibits Rat Urinary Bladder Tumorigenesis1 Gary A. Piazza, W. Joseph Thompson,2 Rifat Pamukcu, Hector W. Alila, Clark M. Whitehead, Li Liu, John R. Fetter, William E. Gresh, Jr., Andres J. Klein-Szanto, Daniel R. Farnell, Isao Eto, and Clinton J. Grubbs Cell Pathways, Inc., Horsham, Pennsylvania 19044 [G. A. P., W. J. T., R. P., H. W. A., C. M. W., L. L., J. R. F., W. E. G.]; Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [A. J. K.]; Southern Research Institute, Birmingham, Alabama 35205 [D. R. F.]; and The University of Alabama at Birmingham, Birmingham, Alabama 35205-7340 [I. E., C. J. G.] ABSTRACT systemic or intravesical delivery of chemotherapeutic drugs, which produce relatively modest efficacy and are associated with serious Exisulind (Aptosyn) is a novel antineoplastic drug being developed for side effects and/or delivery complications. The high rate of mortality the prevention and treatment of precancerous and malignant diseases. In from urinary bladder cancer and the high incidence of disease recur- colon tumor cells, the drug induces apoptosis by a mechanism involving cyclic GMP (cGMP) phosphodiesterase inhibition, sustained elevation of rence emphasize the need for new therapeutic agents alone or in cGMP, and protein kinase G activation. We studied the effect of exisulind combination with existing therapies. Research to identify the specific on bladder tumorigenesis induced in rats by the carcinogen, N-butyl-N- molecular defects involved in bladder tumorigenesis has identified (4-hydroxybutyl) nitrosamine. Exisulind at doses of 800, 1000, and 1200 mutations in a number of genes (i.e., ras and p53) or altered expres- mg/kg (diet) inhibited tumor multiplicity by 36, 47, and 64% and tumor sion of proteins (cyclin D and p21 WAF1/CIP1), which are known to incidence by 31, 38, and 61%, respectively.
    [Show full text]
  • Examination Questions
    EXAMINATION QUESTIONS CHAPTER I. GENERAL PHARMACOLOGY AND PRESCRIPTION 1. Essence of pharmacology as a science. Parts and fields of modern pharmacology. The main terms and concepts of pharmacology – pharmacological activity, action, efficiency. 2. Sources and stages of drug development. Drugs – generics, placebo effects. Definition of such concepts as medicinal agent (medicinal drug, drug), medicinal substance, medicinal form. 3. Routes of drug administration into the body and their characteristic. Presystemic drug elimination. 4. Drug transfer through biological barriers and their types. The main factors influencing on the drug transfer in the body. 5. Drug transfer of variable ionization substances through membranes (Henderson-Hasselbach's equation of ionization). Principles of transfer management. 6. Drug transfer in the body. Aqueous diffusion and lipid diffusion (Fick's diffusion equation). Active transport. 7. Central postulate of pharmacokinetics: concentration of medicinal substance in blood plasma – the main parameter for management of the pharmacological effect. The tasks solved on the basis of this postulate. 8. Pharmacokinetic models (one-compartment and two-compartment), quantitative laws of absorption and drug elimination. 9. Bioavailability of drugs – definition, essence, quantitative expression, determinants. 10. Drug distribution in the body: compartments, ligands, the main determinants of distribution. 11. Elimination rate constant, its essence, dimension, connection with other pharmacokinetic parameters. 12. Excretion half-life of drugs, its essence, dimension, connection with other pharmacokinetic parameters. 13. Clearance as the main parameter of pharmacokinetics for management of the dosing regimen. Its essence, dimension and connection with other pharmacokinetic parameters. 14. Dose. Types of doses. Units of drug dosage. Aims of drug dosage, ways and variants of administration of drugs, dosing interval.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Nitrosamines EMEA-H-A5(3)-1490
    25 June 2020 EMA/369136/2020 Committee for Medicinal Products for Human Use (CHMP) Assessment report Procedure under Article 5(3) of Regulation EC (No) 726/2004 Nitrosamine impurities in human medicinal products Procedure number: EMEA/H/A-5(3)/1490 Note: Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ...................................................................................... 2 1. Information on the procedure ............................................................... 7 2. Scientific discussion .............................................................................. 7 2.1. Introduction......................................................................................................... 7 2.2. Quality and safety aspects ..................................................................................... 7 2.2.1. Root causes for presence of N-nitrosamines in medicinal products and measures to mitigate them............................................................................................................. 8 2.2.2. Presence and formation of N-nitrosamines
    [Show full text]
  • Doxapram Elisa Kit Instructions Product #106219 & 106216 Forensic Use Only
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology DOXAPRAM ELISA KIT INSTRUCTIONS PRODUCT #106219 & 106216 FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Doxapram and/or other metabolites in human urine, blood, oral fluid. DESCRIPTION Neogen Corporation’s Doxapram ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug-enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the diluted drug-enzyme conjugate is added and the mixture is incubated at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed 3 times to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB). After a 30 minute substrate incubation, the reaction is halted with the addition of Red Stop Solution.
    [Show full text]